Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-19. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Mike Morasky (born June 14, 1964) is an American composer, visual effects artist, director and programmer. He composed the scores for the Valve games Team Fortress 2, the Left 4 Dead series, Portal 2, Counter-Strike: Global Offensive, Half-Life: Alyx and Counter-Strike 2. He worked on visual effects for the Lord of the Rings and Matrix films, and founded the underground art bands Steel Pole Bath Tub, Milk Cult and DUH.
List of lymphatic nodes of the human body American Society of Lymphology Glymphatic system and Meningeal lymphatic vessels - equivalent for the central nervous system Innate lymphoid cells Lymphangiogenesis Lymphangion Mononuclear phagocyte system Waldemar Olszewski – discovered fundamental processes in human tissues connected with function of the lymphatic system Trogocytosis
== Clinical trials == Clinical trials for muscular dystrophy have not proven successful in generating functional improvements compared to placebo. Gains of muscle mass were small to non-existent in this population. Research is ongoing on the potential use of myostatin inhibitors for motor neuron diseases like spinal muscle atrophy and amyotrophic lateral sclerosis. Due to myostatin's effect as a negative regulator of bone, its inhibition has also been considered for orthopedic diseases such as rheumatoid arthritis. Myostatin inhibitors were generally able to increase lean body mass and reduce body fat in people with sarcopenia, but the extent to which this translated into functional improvements varied. Bimagrumab showed effectiveness in increasing lean mass and reducing fat mass in obese individuals in a clinical trial.
Sources: en.wikipedia.org
GDPbio: GDPbio (Genome based prediction of Diseases and Personal medicines using Bioinformatics) is a project focused on providing various resources related to genome analysis, particularly for the prediction of disease susceptibility of individuals and personalized medicine development, with the aim of public health improvement. AminoFAST: Functional Annotation Tools for Amino Acids (AminoFAST) is a server designed to serve the bioinformatics community. Its aim is to develop as many tools as possible to understand the function of amino acids in proteins based on protein structure in PDB. The broad knowledge of protein function would help in the identification of novel drug targets.
He added the Lusatias to the Lands of the Bohemian Crown, which then comprised large territories with a significant German population. In the hilly border regions German settlers established major manufactures of forest glass. The situation of the German population was aggravated by the Hussite Wars (1419–1434), though there were also some Germans among the Hussite insurgents. Despite the hardships of the Hussite Wars, the German population remained dominant in the border regions. By then Germans largely settled the hilly Bohemian border regions as well as the cities of the lowlands; mainly people of Bavarian descent in the South Bohemian and South Moravian Region, in Brno, Jihlava, České Budějovice and the West Bohemian Plzeň Region; Franconian people in Žatec; Upper Saxons in adjacent North Bohemia, where the border with the Saxon Electorate was fixed by the 1459 Peace of Eger; Germanic Silesians in the adjacent Sudetes region with the County of Kladsko, in the Moravian–Silesian Region, in Svitavy and Olomouc. The city of Prague had a German-speaking majority from the last third of the 17th century until 1860, but after 1910 the proportion of German speakers had decreased to 6.7% of the population. From the Luxembourgs, rule over Bohemia passed through George of Podiebrad to the Jagiellon dynasty and finally to the House of Habsburg in 1526. Both Czech and German Bohemians suffered heavily in the Thirty Years' War. Bohemia lost 70% of its population.
January 27: Law making gym instruction mandatory in all public education establishments for boys run by the State, Departments, and Municipalities (only for boys). December 21: December 21: Law on Secondary Education for Girls, which opens the doors of secondary education to girls, with specific provisions and a different diploma at the end of their studies from the baccalaureate (which boys can obtain). 1881
In January 2023, Foreign Minister Mauro Vieira announced Brazil's return to the Community of Latin American and Caribbean States (CELAC). During the 7th CELAC summit, Lula expressed support for a modernization of the South American customs union Mercosur and the creation of a common unit of account between Argentina and Brazil which other South American nations could also join to boost regional integration and skip US dollar dominance. On 25 January, during a trip to Uruguay, Lula called for the European Union-Mercosur trade deal to be sealed and a China-Mercosur trade agreement to be explored. Lula and Uruguayan president Luis Lacalle Pou held talks over infrastructure projects to be developed in Uruguay, including a joint Uruguayan-Brazilian administration of the Rivera International Airport. In March 2023, Uruguayan and Brazilian top officials jointly detailed the said infrastructure projects in Brasília. Brazil also invited Paraguay and Uruguay to join the works of the G20 ahead of the 2024 G20 Brazil summit, as Brazilian rotating presidency in the group was to begin on 1 December 2023. In December 2024, during a summit in Montevideo attended by Lula and Ursula von der Leyen, Mercosur struck a definitive free trade agreement with the European Union representing nearly a quarter of the global gross domestic product (GDP).
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.